Skip to main content

Table 3 Candidate predictors from univariable analysis

From: Multivariable regression analysis of febrile neutropenia occurrence in early breast cancer patients receiving chemotherapy assessing patient-related, chemotherapy-related and genetic risk factors

 

FN in any cycle

FN in cycle 1

Variable

OR (95% CI)

p-value

OR (95% CI)

p-value

Platelets (109/L, per 10 units change)

0.96 (0.93; 0.98)

0.002

0.95 (0.92; 0.99)

0.005

ANC (109/L)

0.87 (0.77; 0.98)

0.023

0.86 (0.74; 1.00)

0.046

ALT (U/L, per 10 units change)

1.12 (1.02; 1.23)

0.024

-

-

WBC (109/L)

0.90 (0.83; 0.99)

0.032

0.88 (0.79; 0.99)

0.028

Height (cm)

-

-

1.03 (1.00; 1.07)

0.043

Haemoglobin (g/dl)

0.87 (0.73; 1.02)

0.094

0.80 (0.66; 0.98)

0.030

Planned cycles FEC (6 vs. 3 cycles)

1.09 (0.98; 1.22)

0.129

-

-

ASTa (U/L, per 10 units change)

1.09 (0.95; 1.24)

0.210

-

-

BSA (m2)

-

-

2.44 (0.59; 10.03)

0.217

Creatinin (mg/dl)

2.04 (0.66; 6.33)

0.219

-

-

Planned dose of epirubicin (100 mg/m2)

-

-

1.01 (0.99; 1.02)

0.217

MRP1rs4148350

 

0.000

 

0.004

- GT vs. GG

1.82 (1.12; 2.94)

0.015

2.09 (1.21; 3.61)

0.008

- TT vs. GG

22.06 (2.45; 198.96)

0.006

6.30 (1.04; 38.28)

0.045

MRP1rs45511401b

 

0.000

 

0.004

- GT vs. GG

1.80 (1.12; 2.89)

0.015

1.82 (1.05; 3.17)

0.034

- TT vs. GG

16.40 (1.69; 158.84)

0.016

9.20 (1.28; 66.20)

0.027

MRP1rs246221

 

0.004

 

0.039

- TT vs. CC

0.47 (0.25; 0.86)

0.014

0.49 (0.24; 1.00)

0.053

- TC vs. CC

0.80 (0.44; 1.45)

0.459

0.80 (0.40; 1.61)

0.530

FGFR4rs351855

 

0.098

-

-

- CT vs. CC

1.25 (0.88; 1.77)

0.216

  

- TT vs. CC

0.60 (0.29; 1.24)

0.166

  

CYP3A4rs4986910

 

0.171

-

-

- TC vs. TT

0.24 (0.03; 1.84)

   

XRCC3rs861534

 

0.130

 

0.044

- GG vs. AA

1.25 (0.76; 2.07)

0.381

1.73 (0.91; 3.29)

0.095

- GA vs. AA

0.86 (0.52; 1.42)

0.544

1.03 (0.53; 1.99)

0.930

TYMSrs11280056

 

0.114

-

-

- AAGTTA.DEL vs. AAGTTA

0.88 (0.60; 1.27)

0.486

  

- DEL vs. AAGTTA

1.60 (0.91; 2.82)

0.100

  

GSTP1rs1695

 

0.228

-

-

- AG vs. AA

0.75 (0.53; 1.08)

0.124

  

- GG vs. AA

0.70 (0.40; 1.25)

0.231

  

GSTA1rs3957357

-

-

 

0.163

- GG vs. AA

  

0.95 (0.49; 1.83)

0.875

- GA vs. AA

  

1.45 (0.80; 2.65)

0.223

ALDH3A1rs2228100

-

-

 

0.188

- GG vs. CC

  

1.86 (0.92; 3.76)

0.086

- GC vs. CC

  

1.27 (0.81; 1.98)

0.297

MRP1rs1883112

-

-

 

0.187

- AG vs. AA

  

0.87 (0.52; 1.46)

0.594

- GG vs. AA

  

0.59 (0.32; 1.08)

0.087

UGT2B7rs7439366

-

-

 

0.204

- TT vs. CC

  

1.08 (0.57; 2.04)

0.813

- TC vs. CC

  

1.52 (0.87; 2.65)

0.139

UGT2B7rs7662029

-

-

 

0.204

- GG vs. AA

  

0.93 (0.49; 1.75)

0.813

- GA vs. AA

  

1.41 (0.86; 2.31)

0.174

  1. ALT, alanine aminotransferase; ANC, absolute neutrophil count; AST, aspartate aminotransferase; BMI, body mass index; BSA, body surface area; CI, confidence interval; FEC, fluorouracil, epirubicin and cyclophosphamide; FN, febrile neutropenia; WBC, white blood cell count.
  2. Odds ratios and 95% confidence intervals are reported per 1 unit change if not otherwise indicated.
  3. aHighly correlated with alanine aminotransferase (Pearson’s correlation coefficient 0.76) and not included in multivariable analysis.
  4. bHighly correlated with MRP1rs4148350 (Spearman correlation coefficient 0.81) and not included in multivariable analysis.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us